Biohit Plc B-shares Subscribed with Stock Options I 2021C and I 2022C
Biohit Plc Stock Exchange Release 10, October 2025 at 10.00 a.m. (EEST)
A total number of 12,000 new Biohit Plc’s B-shares have been subscribed for with stock options I 2021C and I 2022C between 14 March 2025 and 5 September 2025. A total of 8,000 new B-shares of the company were subscribed for with the I 2021C stock options and a total of 4,000 new B-shares of the company were subscribed for with the I 2022C stock options. These shares have been entered into the Trade Register on October 10, 2025, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. The new shares will be traded on Nasdaq Helsinki Ltd’s main list together with the existing B-shares on or about October 13, 2025.
The share subscription price was EUR 1.00 per share respectively. The entire subscription price of EUR 12,000.00 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value.
After the subscriptions the number of all Biohit Plc's shares will rise to 15,197,593 shares and B-shares will rise to 12,222,093 shares.
The share subscription period with stock options I 2021C began on March 1, 2025 and ends on March 1, 2028. The option scheme is based on the Biohit Plc board resolution of December 7, 2021 and the Annual General Meeting authorization of September 16, 2020.
The share subscription period with stock options I 2022C began on March 1, 2025 and ends on March 1, 2028. The option scheme is based on the Biohit Plc board resolution of November 28, 2022 and the Annual General Meeting authorization of June 15, 2022.
The terms and conditions of the option schemes with additional information are available on Biohit Plc website at www.biohithealthcare.com.
Additional information:
Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50 383 5948
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com